



## Quantification and phenotyping of circulating tumor cells isolated with the GILUPI CellCollector® technology

GILUPI announces the release of a video article presenting an innovative approach for isolation of circulating tumor cells (CTCs) by the use of the GILUPI CellCollector® and their downstream phenotyping in combination with chromosomal rearrangement detection <sup>[1]</sup>.

CTCs can often be found in the blood of cancer patients. They are a promising surrogate marker for disease progression and response to therapy. CTCs indicate tumor cell extravasation and are prerequisites for formation of metastasis. Detection and characterization of these rare cells could provide a powerful approach for early disease diagnosis as well as disease monitoring. The GILUPI CellCollector® offers medical personnel at any point-of-care with the unique opportunity to enrich these CTCs *in vivo*.

Fabbri and colleagues from Cancer Institute IRST of Meldola in Italy presented a method which combines immunofluorescence staining and DNA FISH analysis of *in vivo* isolated CTCs. They demonstrated the feasibility of this new approach by determination of tumor relevant markers (EpCAM expression and ALK chromosomal translocations) in a lung cancer cell line attached on the medical wire of GILUPI. This new concept will enhance prognostic value of CTCs and provides an innovative strategy for improving personalized cancer treatments.

<sup>[1]</sup> Fabbri *et al.* " Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH." J Vis Exp. 2017 Dec 21;(130). doi: 10.3791/56936.

### About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is today's challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immunocapture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector® is the first *in vivo* CTC isolation product worldwide that is CE approved.

For further information visit [www.gilupi.com](http://www.gilupi.com)